The report covers forecast and analysis for the inhalable drugs market on a global and regional level. The study provides historic data from 2016 along with forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the inhalable drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the inhalable drugs market on a global as well as regional level.
According to the report, global demand for inhalable drugs market was valued at approximately USD 24.89 billion in 2018, and is expected to generate revenue of around USD 39.57 billion by end of 2025, growing at a CAGR of around 6.9% between 2019 and 2025.
In order to give the users of this report a comprehensive view on the inhalable drugs market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the inhalable drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the inhalable drugs market on global and regional basis.
The study provides a crucial view on the inhalable drugs by segmenting the market based on product, application, and region. All the segments of inhalable drugs market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.
Oral and injectable drugs are widely used therapies across the globe. However, use of inhalation route of administration is gaining momentum in the market for delivery of peptide, proteins and other drugs. Pulmonary delivery of systemic drug therapies is widely used for treating mainly refractory ailments and chronic diseases. Inhaled drugs are mainly used in chronic obstructive pulmonary disease (COPD) and asthma, to avoid active pharmaceutical ingredient (API) exposure to harsh environment conditions and gastrointestinal tract enzymes.
The demand for inhalable drugs market is driven by increasing prevalence of chronic non-respiratory diseases like diabetes, infectious diseases, Parkinson’s disease and chronic respiratory diseases such as chronic pulmonary obstructive disease (COPD), asthma etc. Additionally, increasing geriatric population across the globe, technological advancements, increasing R&D spending to bring novel inhalation therapy drugs using nanoparticles, nanocrystals, surfactant carriers are other important factors that boost the market growth. The novel therapy helps in increased systemic availability of drugs and can be conveniently administered over invasive methods, minimal toxicity, and improved drug interactions. However, high cost of inhalable drugs may limit the market growth over the forecast period. Emerging markets with increasing aging population and unmet medical needs are expected to bring growth opportunities over the forecast period for global inhalable drugs market.
Based on product, global inhalable drugs market is segmented into spray, dry powder formulation and aerosol. Dry powder formulation product segment accounted for largest market share in 2018 due to increased efficacy and better performance as compared to other forms. Dry powder formulation segment is expected to witness highest CAGR over the forecast period. Aerosol products will register steady growth in the coming years.
Based on application, inhalable drugs market is categorized into non-respiratory diseases and respiratory diseases. Respiratory diseases segment is sub segmented into chronic obstructive pulmonary disease (COPD), asthma, and other respiratory diseases. Respiratory disease application segment accounted for largest market share in 2018 whereas non-respiratory diseases application segment is projected to witness highest growth over the forecast period. Increasing preference for non-invasive or minimally invasive therapies is expected to drive the demand for inhalable drugs in other non-respiratory diseases.
North America dominated the global inhalable drugs market in 2018. Presence of developed healthcare infrastructure, increasing prevalence of respiratory diseases, presence of major players, increasing R&D investments for novel therapy development are factors driving the market in this region. Europe was second largest regional market. Increasing awareness, favorable reimbursement policies and increasing prevalence of respiratory disorders are major factors that boost market growth in this region. Latin America is expected to witness moderate growth over the forecast period. Asia Pacific region will exhibit highest growth for inhalable drugs market during the forecast period. Increasing geriatric population with high susceptibility to chronic respiratory disorders and other non-respiratory diseases, increasing healthcare expenditure, growing prevalence of asthma, COPD are factors promoting inhalable drugs market growth in Asia Pacific. Middle East and Africa region is projected to show considerable growth in coming years.
Major players included in the report are Cipla Inc., Boehringer Ingelheim International GmbH, Mundipharma, GlaxoSmithKline, Mylan, Vectura, Sanofi, and AstraZeneca among others.
The report segment of global inhalable drugs market as follows:
Global Inhalable Drugs Market: By Product
Global Inhalable Drugs Market: By Application
Global Inhalable Drugs Market: By Region
According to the report, global demand for inhalable drugs market was valued at approximately USD 24.89 billion in 2018, and is expected to generate revenue of around USD 39.57 billion by end of 2025, growing at a CAGR of around 6.9% between 2019 and 2025.
In order to give the users of this report a comprehensive view on the inhalable drugs market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the inhalable drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the inhalable drugs market on global and regional basis.
The study provides a crucial view on the inhalable drugs by segmenting the market based on product, application, and region. All the segments of inhalable drugs market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.
Oral and injectable drugs are widely used therapies across the globe. However, use of inhalation route of administration is gaining momentum in the market for delivery of peptide, proteins and other drugs. Pulmonary delivery of systemic drug therapies is widely used for treating mainly refractory ailments and chronic diseases. Inhaled drugs are mainly used in chronic obstructive pulmonary disease (COPD) and asthma, to avoid active pharmaceutical ingredient (API) exposure to harsh environment conditions and gastrointestinal tract enzymes.
The demand for inhalable drugs market is driven by increasing prevalence of chronic non-respiratory diseases like diabetes, infectious diseases, Parkinson’s disease and chronic respiratory diseases such as chronic pulmonary obstructive disease (COPD), asthma etc. Additionally, increasing geriatric population across the globe, technological advancements, increasing R&D spending to bring novel inhalation therapy drugs using nanoparticles, nanocrystals, surfactant carriers are other important factors that boost the market growth. The novel therapy helps in increased systemic availability of drugs and can be conveniently administered over invasive methods, minimal toxicity, and improved drug interactions. However, high cost of inhalable drugs may limit the market growth over the forecast period. Emerging markets with increasing aging population and unmet medical needs are expected to bring growth opportunities over the forecast period for global inhalable drugs market.
Based on product, global inhalable drugs market is segmented into spray, dry powder formulation and aerosol. Dry powder formulation product segment accounted for largest market share in 2018 due to increased efficacy and better performance as compared to other forms. Dry powder formulation segment is expected to witness highest CAGR over the forecast period. Aerosol products will register steady growth in the coming years.
Based on application, inhalable drugs market is categorized into non-respiratory diseases and respiratory diseases. Respiratory diseases segment is sub segmented into chronic obstructive pulmonary disease (COPD), asthma, and other respiratory diseases. Respiratory disease application segment accounted for largest market share in 2018 whereas non-respiratory diseases application segment is projected to witness highest growth over the forecast period. Increasing preference for non-invasive or minimally invasive therapies is expected to drive the demand for inhalable drugs in other non-respiratory diseases.
North America dominated the global inhalable drugs market in 2018. Presence of developed healthcare infrastructure, increasing prevalence of respiratory diseases, presence of major players, increasing R&D investments for novel therapy development are factors driving the market in this region. Europe was second largest regional market. Increasing awareness, favorable reimbursement policies and increasing prevalence of respiratory disorders are major factors that boost market growth in this region. Latin America is expected to witness moderate growth over the forecast period. Asia Pacific region will exhibit highest growth for inhalable drugs market during the forecast period. Increasing geriatric population with high susceptibility to chronic respiratory disorders and other non-respiratory diseases, increasing healthcare expenditure, growing prevalence of asthma, COPD are factors promoting inhalable drugs market growth in Asia Pacific. Middle East and Africa region is projected to show considerable growth in coming years.
Major players included in the report are Cipla Inc., Boehringer Ingelheim International GmbH, Mundipharma, GlaxoSmithKline, Mylan, Vectura, Sanofi, and AstraZeneca among others.
The report segment of global inhalable drugs market as follows:
Global Inhalable Drugs Market: By Product
- Dry Powder Formulation
- Aerosol
- Spray
Global Inhalable Drugs Market: By Application
- Respiratory Diseases
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Other Respiratory Diseases
- Non-Respiratory Diseases
Global Inhalable Drugs Market: By Region
- North America
- U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Middle East and Africa
Table of Contents
- Chapter 1. Preface
- 1.1. Report Description and Scope
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
- Chapter 2. Executive Summary
- 2.1. Inhalable Drugs Market, 2016 - 2025, (USD Million)
- 2.2. Inhalable Drugs Market: Snapshot
- Chapter 3. Global Inhalable Drugs Market - Industry Analysis
- 3.1. Inhalable Drugs Market: Market Dynamics
- 3.2. Market Drivers
- 3.2.1. Rising Prevalence of Chronic Respiratory Disorders
- 3.2.2. Increasing Preference for Novel Therapies
- 3.3. Restraints
- 3.3.1. High Cost of Inhalable Drugs
- 3.4. Opportunity
- 3.4.1. Emerging Markets
- 3.5. Porter's Five Forces Analysis
- 3.6. Market Attractiveness Analysis
- 3.6.1. Market attractiveness analysis by product segment
- 3.6.2. Market attractiveness analysis by application segment
- 3.6.3. Market attractiveness analysis by regional segment
- Chapter 4. Global Inhalable Drugs Market - Competitive Landscape
- 4.1. Company market share analysis
- 4.1.1. Global inhalable drugs market: company market share analysis, 2018
- 4.2. Strategic development
- 4.2.1. Acquisitions & mergers
- 4.2.2. New product launches
- 4.2.3. Agreements, partnerships, collaborations and joint ventures
- 4.2.4. Research and development and regional expansion
- 4.1. Company market share analysis
- Chapter 5. Global Inhalable Drugs Market - Product Segment Analysis
- 5.1. Global inhalable drugs market overview: by product
- 5.1.1. Global inhalable drugs market revenue share, by product, 2018 and 2025
- 5.2. Dry Powder Formulation
- 5.2.1. Global inhalable drugs market by Dry Powder Formulation, 2016-2025 (USD Million)
- 5.3. Aerosol
- 5.3.1. Global inhalable drugs market by Aerosol, 2016-2025 (USD Million)
- 5.4. Spray
- 5.4.1. Global inhalable drugs market by Spray, 2016-2025 (USD Million)
- 5.1. Global inhalable drugs market overview: by product
- Chapter 6. Global Inhalable Drugs Market - Application Segment Analysis
- 6.1. Global inhalable drugs market overview: by application
- 6.1.1. Global inhalable drugs market revenue share, by application, 2018 and 2025
- 6.2. Respiratory Diseases
- 6.2.1. Global inhalable drugs market by Respiratory Diseases, 2016-2025 (USD Million)
- 6.2.2. Chronic Obstructive Pulmonary Disease (COPD)
- 6.2.2.1. Global inhalable drugs market by Chronic Obstructive Pulmonary Disease (COPD), 2016-2025 (USD Million)
- 6.2.3. Asthma
- 6.2.3.1. Global inhalable drugs market by Asthma, 2016-2025 (USD Million)
- 6.2.4. Other Respiratory Diseases
- 6.2.4.1. Global inhalable drugs market by Other Respiratory Diseases, 2016-2025 (USD Million)
- 6.3. Non-respiratory Diseases
- 6.3.1.1. Global inhalable drugs market by Non-respiratory Diseases, 2016-2025 (USD Million)
- 6.1. Global inhalable drugs market overview: by application
- Chapter 7. Global Inhalable Drugs Market - Regional Analysis
- 7.1. Global inhalable drugs market overview: by region
- 7.1.1. Global inhalable drugs market revenue share, by region, 2018 and 2025
- 7.2. North America
- 7.2.1. North America inhalable drugs market, by country, 2016-2025 (USD Million)
- 7.2.2. North America inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.2.3. North America inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.2.4. The U.S.
- 7.2.4.1. The U.S. inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.2.4.2. The U.S. inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.2.5. Rest of North America
- 7.2.5.1. Rest of North America inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.2.5.2. Rest of North America inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.3. Europe
- 7.3.1. Europe inhalable drugs market, by country, 2016-2025 (USD Million)
- 7.3.2. Europe inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.3.3. Europe inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.3.4. U.K.
- 7.3.4.1. U.K. inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.3.4.2. U.K. inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.3.5. France
- 7.3.5.1. France inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.3.5.2. France inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.3.6. Germany
- 7.3.6.1. Germany inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.3.6.2. Germany inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.3.7. Rest of Europe
- 7.3.7.1. Rest of Europe inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.3.7.2. Rest of Europe inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific inhalable drugs market, by country, 2016-2025 (USD Million)
- 7.4.2. Asia Pacific inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.4.3. Asia Pacific inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.4.4. China
- 7.4.4.1. China inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.4.4.2. China inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.4.5. Japan
- 7.4.5.1. Japan inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.4.5.2. Japan inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.4.6. India
- 7.4.6.1. India inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.4.6.2. India inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.4.7. Rest of Asia Pacific
- 7.4.7.1. Rest of Asia Pacific inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.4.7.2. Rest of Asia Pacific inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America inhalable drugs market, by country, 2016-2025 (USD Million)
- 7.5.2. Latin America inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.5.3. Latin America inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.5.4. Brazil
- 7.5.4.1. Brazil inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.5.4.2. Brazil inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.5.5. Rest of Latin America
- 7.5.5.1. Rest of Latin America inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.5.5.2. Rest of Latin America inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.6. Middle East & Africa
- 7.6.1. Middle East & Africa inhalable drugs market, 2016-2025 (USD Million)
- 7.6.2. Middle East & Africa inhalable drugs market revenue, by product, 2016-2025 (USD Million)
- 7.6.3. Middle East & Africa inhalable drugs market revenue, by application, 2016-2025 (USD Million)
- 7.1. Global inhalable drugs market overview: by region
- Chapter 8. Company Profiles
- 8.1. Cipla Inc.
- 8.1.1. Overview
- 8.1.2. Financials
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategy
- 8.1.5. Recent Developments
- 8.2. Mundipharma
- 8.2.1. Overview
- 8.2.2. Financials
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategy
- 8.2.5. Recent Developments
- 8.3. Boehringer Ingelheim International GmbH
- 8.3.1. Overview
- 8.3.2. Financials
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategy
- 8.3.5. Recent Developments
- 8.4. GlaxoSmithKline
- 8.4.1. Overview
- 8.4.2. Financials
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategy
- 8.4.5. Recent Developments
- 8.5. Mylan
- 8.5.1. Overview
- 8.5.2. Financials
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategy
- 8.5.5. Recent Developments
- 8.6. Vectura
- 8.6.1. Overview
- 8.6.2. Financials
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategy
- 8.6.5. Recent Developments
- 8.7. Sanofi
- 8.7.1. Overview
- 8.7.2. Financials
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategy
- 8.7.5. Recent Developments
- 8.8. AstraZeneca
- 8.8.1. Overview
- 8.8.2. Financials
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategy
- 8.8.5. Recent Developments
- 8.1. Cipla Inc.
